Travere Therapeutics Relocates Principal Executive Offices

TL;DR

Travere Therapeutics moved its HQ to San Diego, CA.

AI Summary

On September 26, 2024, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130. This move is effective as of the report date.

Why It Matters

A change in principal executive offices can signal operational shifts or strategic realignments within the company.

Risk Assessment

Risk Level: low — This filing reports a change of address for the company's principal executive offices, which is a routine administrative event with no immediate financial or operational risk.

Key Players & Entities

• Travere Therapeutics, Inc. (company) — Registrant
• 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (location) — New Principal Executive Offices
• September 26, 2024 (date) — Report Date

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share TVTX The Nasdaq Global Marke

Filing Documents

• tvtx-20240926.htm (8-K) — 35KB
• 0001438533-24-000038.txt ( ) — 161KB
• tvtx-20240926.xsd (EX-101.SCH) — 2KB
• tvtx-20240926_lab.xml (EX-101.LAB) — 22KB
• tvtx-20240926_pre.xml (EX-101.PRE) — 13KB
• tvtx-20240926_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On September 26, 2024, Travere Therapeutics, Inc. (the "Company") announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study. Patients currently enrolled in pegtibatinase studies continue to receive study medication from small scale batches which are unaffected by the scale-up process. Currently enrolled patients will be able to continue on study medication as scheduled for the duration of the trials they are participating in. The voluntary enrollment pause was enacted following the Company's determination that the desired drug substance profile was not achieved in the recent scale-up process. The Company is in the process of notifying all study investigators of the decision to pause enrollment of new patients into the study until additional material is available. The Company expects to further evaluate the necessary commercial process improvements to enable the continuation of the Phase 3 program and anticipates the earliest date to restart enrollment in the Phase 3 HARMONY Study will be in 2026.

Forward-Looking Statements

Forward-Looking Statements This report contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words "on-track," "positioned," "look forward to," "will," "would," "may," "might," "believes," "anticipates," "plans," "expects," "intends," "potential," or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements and expectations regarding future process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study, and related timing expectations; and statements regarding ongoing clinical trials, including statements regarding medication for patients currently enrolled in such trials. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with manufacturing processes and improvements, and risks related to the regulatory review and approval process, as well as risks and uncertainties associated with the Company's business and finances in general, the success of its commercial products and risks and uncertainties associated with its preclinical and clinical stage pipeline. Specifically, the Company faces risks associated with the challenges of manufacturing scale-up, the ongoing commercial launch of FILSPARI, market acceptance of its commercial products including efficacy, safety, price, reimbursem

View Full Filing

View this 8-K filing on SEC EDGAR